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Abstract
Cas9-based technologies have transformed genome engineering and the interrogation of genomic 
functions, but methods to control such technologies across numerous dimensions—including dose, 
time, specificity, and mutually exclusive modulation of multiple genes—are still lacking. We 
conferred such multidimensional controls to diverse Cas9 systems by leveraging small-molecule-
regulated protein degron domains. Application of our strategy to both Cas9-mediated genome 
editing and transcriptional activities opens new avenues for systematic genome interrogation.
RNA-guided endonucleases, such as Cas9, can be easily targeted to any genomic locus 
through the use of single guide RNAs (sgRNAs)1,2, ushering in a slew of transformative 
technologies. For example, Cas9 enables facile genomic alterations, as well as robust self-
propagation of such alterations throughout a species population via gene drives3. 
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Furthermore, catalytically inactive Cas9 (dCas9) can be fused to a wide range of effectors, 
such as fluorescent proteins for genome imaging4, enzymes that modify DNA or histones for 
epigenome editing5, and transcription-regulating domains for controlling endogenous gene 
expression6.
Despite such advances, a need exists for methods to precisely regulate Cas9 activities across 
multiple dimensions, including dose, target, and time7. Finely tuned control of Cas9 levels is 
important8, as high Cas9 leads to elevated off-target genomic alterations. Rapid disabling of 
Cas9 activity after a desired genomic modification is also valuable to prevent off-target 
activity9. In the context of gene regulation by dCas9-based transcriptional activators, dose-
based control of transcript expression is essential to permit induction of physiologically 
relevant levels of mRNA transcripts. Capability to rapidly reverse transcript induction and to 
control the expression of multiple transcripts independently is also highly desirable. Ideally, 
methods that provide such controls should be readily adaptable to newly emerging RNA-
guided nucleases.
We sought small-molecule-regulated systems that would fulfill these needs. Previously, we 
applied destabilized domains (DDs)10–12 to confer similar controls on transcription 
factors13,14. Briefly, structurally unstable protein domains derived from Escherichia coli 
dihydrofolate reductase (DHFR)10 or the estrogen receptor (ER50)11 are fused to a 
transcription factor. These largely unfolded domains target the fusion protein for rapid 
proteasomal degradation. Small molecules that can bind and stabilize the DDs in their 
poorly populated folded state prevent proteasomal degradation of the fusion protein in a 
concentration-dependent manner, allowing transcription factor function13,14. We envisioned 
that such small-molecule-regulated DDs could be similarly deployed to establish Cas9 
systems with multidimensional control of genome editing and transcriptional activities.
We began by linking the DHFR DD to the N terminus of catalytically inactive Streptococcus 
pyogenes Cas9 (dSpCas9) fused to a VP16-based transcriptional activation domain (e.g., 
VP64 or VP192)15. The addition of trimethoprim (TMP), a DHFR-stabilizing small 
molecule, to cells transfected with either DHFR.dSpCas9. VP64 or a 
DHFR.dSpCas9.VP192 fusion construct16 and appropriate sgRNAs yielded minimal 
induction of target genes or high basal activity (Supplementary Results, Supplementary Fig. 
1). These findings were expected, as dSpCas9.VP64 alone is insufficient for inducing the 
transcription of many target genes17.
We shifted our focus to a second-generation Cas9-based transcription system17 in which 
sgRNAs bear an RNA aptamer that recruits transcription activation domains (e.g., PP7.VP64 
(ref. 18)) to dSpCas9. We imparted conditional activity to this system by fusing the DHFR 
DD to the PP7.VP64 transcription activation domain (Fig. 1a). Cells transiently expressing 
DHFR.PP7.VP64, dSpCas9, and an sgRNA targeting IL1RN showed robust upregulation of 
IL1RN mRNA after treatment with TMP, demonstrating ‘chemical’ control of transcript 
induction (Fig. 1a and Supplementary Fig. 2). Importantly, we observed minimal basal 
transcriptional activation in vehicle-treated samples.
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Existing small-molecule-regulated dCas9 transcriptional activators leave transcription 
continuously on7,19, in contrast to biological systems in which both activation and cessation 
of transcription are often strictly regulated. An advantage of our approach is the potential for 
turning off transcription after removal of the DD-stabilizing small molecule. We treated cells 
transfected with DHFR.PP7.VP64, dSpCas9, and sgRNA with TMP to upregulate 
endogenous genes before a chase period with media lacking TMP (Fig. 1b). Removal of 
TMP resulted in rapid depletion of induced mRNA transcript levels within <8 h for multiple 
genes (Fig. 1b and Supplementary Fig. 3). Thus, our system was shown to permit user-
defined turn-on and turn-off of endogenous gene transcription.
Another attractive feature of our strategy is that several orthogonal small molecule–degron 
pairs exist10,11, theoretically enabling independent control of the transcription of multiple 
genes. For example, the ER50 DD stabilized by the small molecule (Z)-4-hydroxytamoxifen 
(4OHT)11 is orthogonal to the TMP–DHFR pair. Conveniently, the cognate RNA aptamer of 
the transcription activation domain MS2.p65.HSF1 is distinct from that bound by the 
PP7.VP64 domain, and therefore MS2.p65.HSF1 is functionally orthogonal to PP7.VP64 
(refs. 17,18). Similar to our previous observations in experiments with DHFR.PP7.VP64 and 
TMP, expression of ER50.MS2.p65.HSF1 with dSpCas9 and an appropriate sgRNA yielded 
4OHT-dependent transcript induction (Fig. 1c). Immunoblotting confirmed that this 
induction was accompanied by a 4OHT-dependent increase in the amount of 
ER50.MS2.p65.HSF1 protein (Supplementary Fig. 4). As expected, we observed a similar 
increase in amounts of ER50.MS2.p65.HSF1 protein after proteasome inhibition using 
MG-132, confirming that 4OHT rescues the transcription activation domain from 
degradation (Supplementary Fig. 4). Most important, co-expression of both 
DHFR.PP7.VP64 and ER50.MS2.p65.HSF1, along with dSpCas9 and appropriate sgRNAs, 
permitted conditional and orthogonal activation of multiple endogenous genes when TMP, 
4OHT, or both TMP and 4OHT were added to cells (Fig. 1c). We note that the ER50 DD can 
also be deployed to regulate the activity of catalytically inactive Staphylococcus aureus Cas9 
(ref. 20), a Cas9 variant with distinct sgRNAs (Supplementary Fig. 5), highlighting the ready 
adaptability of our approach to next-generation RNA-guided, dCas9-based transcriptional 
activators.
Meaningful interrogation of gene function frequently requires the ability to dose-control 
transcript levels across a wide dynamic range. The pharmacologic chaperoning-based 
mechanism of DD stabilization can engender a broad range of dose control13,14. Indeed, as 
shown in Figure 1d, we were able to control the levels of TMP-mediated IL1RN mRNA 
induction in the DHFR-regulated PP7. VP64 transcription activation domain across orders of 
magnitude simply by modulating the dose of TMP. ASCL1 mRNA upregulation was 
controlled across a similar range by modulation of the 4OHT dose in cells expressing the 
ER50.MS2.p65.HSF1 transcription activation domain (Fig. 1d). This precise tuning of 
transcriptional activity demanded little optimization of expression levels of dCas9, sgRNA, 
or transcription activation domains.
These data demonstrated ‘chemical’ control of endogenous gene transcription across several 
dimensions, including dose, time, and orthogonal modulation of multiple genes. Next, we 
sought to engineer catalytically active Cas9 variants displaying dose-dependent and 
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temporal control of nuclease activity and specificity. Such systems would enable regulated 
and specific genome editing. Temporal control of nuclease activity may also have uses in 
emerging technologies, including gene drives3,21. Consistent with our observations for 
dSpCas9.VP64 (Supplementary Fig. 1), we found that the fusion of a DHFR or ER50 DD to 
the N or C terminus of catalytically active SpCas9 resulted in limited small-molecule control 
(Supplementary Fig. 6). In contrast, fusing DHFR or ER50 DDs to both N and C termini of 
SpCas9 (e.g., DHFR.SpCas9.DHFR) was more successful (Supplementary Fig. 6), providing 
inducible control of nuclease activity. Immunoblotting illustrated the accompanying TMP- 
or 4OHT-dependent increases in amounts of DHFR.SpCas9.DHFR and ER50. SpCas9.ER50 
protein (Supplementary Fig. 7). Furthermore, we observed strongly dose-dependent control 
of gene editing activity for both of our DD.SpCas9.DD constructs (Supplementary Fig. 8), 
with basal activity similar to that previously reported for SpCas9 regulated by intein self-
splicing22 (Supplementary Fig. 9).
Off-target activity of Cas9 nucleases can lead to catastrophic biological events, including 
chromosomal translocations23. Truncation of sgRNAs substantially enhances Cas9 
specificity, and nickase variants, FokI–dCas9 nuclease, and high-fidelity Cas9 variants also 
offer improvements23. We anticipated that the precise regulation of Cas9 levels afforded by 
fusion to small-molecule-controlled DDs would allow us to titer in optimal Cas9 
concentrations to maximize gene editing on-target while minimizing it off-target22,24. 
Indeed, we observed enhanced specificity for on-target versus known off-target sites of 
VEGFA and EMX1 after administering optimized doses of TMP or 4OHT for the 
DHFR.SpCas9.DHFR and the ER50.SpCas9. ER50 systems, respectively (Fig. 2a–d, 
Supplementary Table 1, and Supplementary Figs. 10 and 11).
Limiting Cas9 activity to a short temporal window is another promising avenue for 
enhancing genome editing specificity and has been accomplished previously via the delivery 
of a ribonucleopro-tein complex of Cas9 and sgRNA25. Using DD-regulated Cas9, one 
should be able to further control the size of the temporal window (as demonstrated in Fig. 
1b). In the context of gene editing, this feature is illustrated by our observation that a short 
(6 h) pulse of TMP in U2OS.eGFP-PEST cells co-expressing DHFR.SpCas9.DHFR and 
eGFP-targeting sgRNAs resulted in considerably less eGFP knockout than a 48-h pulse over 
the same time course (Fig. 2e). We note that it is straightforward to extend our modular 
method to other next-generation RNA-guided endonucleases (demonstrated, for example, in 
Supplementary Fig. 12).
In summary, ‘chemical’ control of Cas9 endowed by DD fusion enables robust control of 
genome-interrogating activities across multiple dimensions, including dose, time, gene 
targets, and specificity. The small molecules used are inexpensive and nontoxic and display 
favorable pharmacologic properties, and TMP is able to cross the blood–brain barrier. Our 
methodology is easily transportable to other cells and to complex organisms6, enabling not 
just biomedical applications but also control of CRISPR-based gene drives. Finally, our 
modular approach should prove readily extensible to emerging next-generation RNA-guided 
endonucleases.
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ONLINE METHODS
Reagents and plasmids
Trimethoprim was purchased from Alfa Aesar (J63053, ≥98% purity, validated by LC-MS 
and stabilization of a fluorescent positive control construct, DHFR.YFP). (Z)-4-
hydroxytamoxifen was purchased from Sigma-Aldrich (H7904, ≥98% purity, validated by 
LC-MS and stabilization of a fluorescent positive control construct, ER50.YFP). 
Lipofectamine 2000 (Life Technologies) was used as a transfecting agent according to the 
manufacturer’s protocol. Plasmid sequences for DD-fused Cas9 and transcription activation 
domain constructs are included in the Supplementary Note.
Cell culture
All cells were cultured at 37 °C in a 5% CO2 atmosphere. HEK293T cells (Life 
Technologies) used in transcriptional activation experiments were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) (CellGro) supplemented with 10% FBS (CellGro) and 
1% penicillin–streptomycin–glutamine (CellGro). HEK293T cells used in surveyor assays 
and nuclease specificity experiments and U2OS.eGFP-PEST cells26 stably integrated with 
an eGFP-PEST fusion gene were maintained in DMEM (Life Technologies) supplemented 
with 10% FBS, 1× penicillin–streptomycin–glutamax (Life Technologies) and 400 μg/mL of 
the selection antibiotic G418 (for the U2OS. eGFP-PEST cells). Cells were continuously 
maintained at <90% confluency. All cell lines were sourced commercially or were 
functionally validated. Cells were periodically tested for mycoplasma contamination using 
the MycoAlert PLUS Mycoplasma Detection Kit (Lonza).
Transcription activation experiments and quantitative RT-PCR analyses
Transient transfections of HEK293T cells (750,000 cells per well in a six-well plate format) 
were carried out with an equivalent mass of each plasmid (dCas9, destabilized domain 
effector, and sgRNA) for a total mass of 5 μg of plasmid DNA. 24 h after transfection, cells 
were treated with the appropriate dose of DD-stabilizing small molecule(s), as indicated, for 
18 h before harvesting and subsequent RNA extraction using the EZNA Total RNA Kit I 
(Omega). For reversibility experiments, cells were treated 24 h after transfection with 100 
nM TMP for 18 h, at which point cells were treated with fresh media either containing 100 
nM TMP or lacking TMP. After the media swap, cells were incubated in fresh media before 
harvesting and subsequent RNA extraction using the EZNA Total RNA Kit I (Omega). 
qPCR reactions were performed on cDNA prepared from 1,000 ng of total cellular RNA 
using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems). TaqMan 
qPCR probes (Life Technologies; Supplementary Table 2) or other primers (Supplementary 
Table 3) and Fast Advanced Master Mix (Life Technologies) were used in 5-μl multiplexed 
reactions and 384-well format in a Light Cycler 480 II Real-Time PCR machine. All 
measurements were performed at least in triplicate. Data were analyzed using the 
LightCycler 480 Software, version 1.5 (Roche), by the ΔΔCt method: target gene Ct values 
(FAM dye) were normalized to GAPDH Ct values (VIC dye), and fold changes in target 
gene expression were normalized to RFP-transfected experimental controls. Analyzed data 
are reported as the mean ± s.d. for technical replicates, or mean ± s.e.m. for biological 
replicates.
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Next-generation sequencing of Cas9-mediated genome modifications
HEK293T cells (130,000 cells per well in a 24-well plate format) were transiently 
transfected with 400 ng of Cas9 plasmid and 100 ng of the EMX1(1) sgRNA expression 
plasmid in the presence or absence of TMP or 4OHT, as appropriate27. Transfection of an 
eGFP-encoding plasmid was used as a control. We extracted genomic DNA 72 h after 
transfection using the QuickExtract DNA extraction kit (Epicentre) by incubating the cell 
suspension at 65 °C for 15 min, 68 °C for 15 min, and 98 °C for 10 min. Next-generation 
sequencing samples were prepared via two-step PCR (Supplementary Table 4) according to 
a previously reported protocol28. In the first step, PCR was performed to amplify the target 
gene of interest and introduce adaptors. In the second step, PCR was used to attach Illumina 
P5 adaptors with barcodes, after which PCR products were isolated via gel purification. 
DNA concentrations were determined using the Qubit dsDNA HS Assay Kit (Life 
Technologies) and processed for NGS analysis using the MiSeq Reagent Kit v2 300 
(Illumina) according to the manufacturer’s protocol.
Analysis of Cas9 nuclease activity via disruption of genomic eGFP-PEST
Approximately 200,000 U2OS.eGFP-PEST cells were nucleofected in duplicate with 500 ng 
of Cas9 and sgRNA expressing plasmids along with a Td-tomato-encoding plasmid using 
the SE Cell Line 4D-Nucleofector X Kit (Lonza) according to the manufacturer’s protocol. 
Approximately 30,000 transfected cells per well in five replicates were plated in a 96-well 
plate (Corning 3904 clear-bottom) and incubated with the indicated quantities of TMP or 
4OHT for 48 h. Cells were fixed using 4% paraformaldehyde, and HCS NuclearMask Blue 
Stain (Life Technologies) was used as the nuclear counterstaining agent. Imaging was 
performed with an IXM 137204 ImageXpress Automated High Content Microscope 
(Molecular Devices) at 4× magnification under three excitation channels (blue, green, and 
red) with nine acquisition sites per well. Images were analyzed in the MetaXpress software, 
and data were plotted using GraphPad Prism 6.
Western blot analyses
Cells transiently expressing the different constructs were incubated in either the absence or 
the presence of stabilizing small molecules (TMP or 4OHT) for 24 h or with the proteasome 
inhibitor MG-132 for 12 h before harvesting. Cell suspensions were spun down at 1,000g for 
5 min and processed according to one of two different protocols. In protocol 1 (total cell 
lysis), cells were resuspended in RIPA buffer (150 mM sodium chloride, 1.0% Triton X-100, 
0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate, and 50 mM Tris, pH 7.5) and 
incubated at 4 °C for 10 min. The cell suspensions were then vortexed for 10 min at 4 °C 
and spun down at 16,000g for 15 min at 4 °C. The supernatant was transferred to a fresh 
tube and processed for immunoblotting. In protocol 2 (nuclear extraction, cell pellets were 
resuspended in buffer A (10 mM HEPES, pH 7.5, 50 mM NaCl, 0.5 M sucrose, 0.1 mM 
EDTA, 0.5% Triton X-100, and protease inhibitors) and incubated on ice for 10 min. Cell 
suspensions were centrifuged at 1,000g for 5 min at 4 °C and the post-nuclear supernatant 
was transferred to a separate tube. Cell pellets were washed once with buffer A followed by 
buffer B (10 mM HEPES, pH 7.5, 10 mM KCl, 0.1 mM EDTA, and 0.1 mM EGTA). 
Finally, the cell pellets were resuspended in buffer C (10 mM HEPES, pH 7.5, 500 mM 
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NaCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.1% IGEPAL (NP40), and protease inhibitors) and 
vortexed for 15 min at 4 °C. The cell suspensions were centrifuged at 16,000g at 4 °C. The 
resulting nuclear extract in the supernatant was transferred to a fresh tube and processed for 
immunoblotting. In a typical immunoblotting protocol, 40 μg of normalized proteins were 
resuspended in the appropriate lysis buffer and electrophoresed on an 8% Bis-Tris gel with 
SDS-Tris running buffer. The protein bands were transferred to a nitrocellulose membrane 
and probed with anti-HSF1(c) (Abcam, ab52757; 1:100,000), anti-Cas9 (Abcam, ab191468; 
1:1,000), anti-actin as a loading control for total cell lysates (Sigma, a1978; 1:10,000), 
and/or anti-H3K27me2 as a loading control for nuclear extracts (Cell Signaling 
Technologies, 9728; 1:1,000). After blocking and incubation with primary antibodies, 
membranes were incubated with 680-nm or 800-nm fluorophore-labeled secondary 
antibodies (LI-COR Biosciences; 1:10,000) before detection using a LI-COR Biosciences 
Odyssey Imager. Images were processed in Image Studio Lite, version 3.1.4 (LI-COR 
Biosciences).
Surveyor nuclease assay
The small-molecule-mediated control of the DHFR. SaCas9.DHFR and ER50.SaCas9.ER50 
gene editing systems was investigated by SURVEYOR nuclease assay29. Briefly, HEK293T 
cells (130,000 cells per well in a 24-well plate) were transiently transfected with 150 ng of 
either SaCas9 or DD.SaCas9.DD constructs (DHFR.SaCas9.DHFR or ER50.SaCas9.ER50) 
along with an EXM1(7)-targeting sgRNA-expressing plasmid. The cells were incubated with 
or without appropriate DD-stabilizing small molecules (TMP: 0, 50, 500, or 5,000 nM; 
4OHT: 0, 10, 100, or 1,000 nM) for 72 h post-transfection at 37 °C. After cell harvesting, the 
genomic DNA was isolated using the QuickExtract DNA extraction kit (Epicentre). 
Genomic DNA was then subjected to PCR using primers corresponding to 157 bp in the 
EMX1(7) gene segment (Supplementary Table 5) and the amplicons were purified with the 
QIAQuick PCR purification kit. The isolated amplicons were normalized and subjected to a 
quick-annealing protocol (ramp 0.03 °C/s), after which they were incubated with Surveyor 
nuclease S (Surveyor Mutation Detection Kits, IDT) at 42 °C for 1 h. For analysis, the 
samples were run on a TBE gel and the cleavage bands were visualized by staining with 
SYBR Gold (Supplementary Fig. 12). Indel frequencies were calculated using the equation 
Indel frequency = 100(1 − √(1 − ((b + c)/(a + b + c)))), where a is the intensity of the 
undigested PCR band and b and c are the intensities of the cleaved bands.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Multidimensional ‘chemical’ control of endogenous transcript levels
(a) Top, small-molecule-mediated transcription induction via a destabilized domain-fused 
transcription activation domain (DHFR.PP7. VP64), dSpCas9, and an sgRNA. Bottom, 
HEK293T cells transfected with dSpCas9 and an RFP control, PP7.VP64, or TMP-regulated 
DHFR.PP7.VP64 targeted to IL1RN were treated with 10 μM TMP for 18 h before qPCR 
analysis. (b) Rapid turn-off of transcription. Cells were transfected and treated with 100 nM 
TMP to upregulate endogenous IL1RN (additional biological replicates are shown in 
Supplementary Fig. 3) or NANOG. After 18 h of TMP treatment, cells were provided with 
fresh media containing or lacking TMP before harvesting and analysis by qPCR. (c) 
Independent, small-molecule-mediated control of transcript expression for two genes in cells 
expressing dSpCas9 and two orthogonal destabilized domain-regulated transcription 
activation domains. DHFR.PP7.VP64 was targeted to IL1RN, and ER50.MS2. p65.HSF1 
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was targeted to ASCL1. Transfected cells were treated as indicated (TMP, 100 nM; 4OHT, 
10 nM) for 18 h before qPCR analysis. (d) Highly dose-responsive endogenous gene 
upregulation in cells transfected with dSpCas9, appropriate sgRNAs, and either 
DHFR.PP7.VP64 (left) or ER50. MS2.p65.HSF1 (right) targeted to IL1RN or ASCL1, 
respectively. Transfected cells were treated with increasing concentrations of TMP or 4OHT 
for 18 h before qPCR analysis. Error bars represent ±s.e.m. from biological replicates (n = 3; 
a,c) or ±s.d. across technical replicates (n = 4; b,d).
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Figure 2. Dose and temporal regulation of DD.SpCas9.DD-mediated insertion/deletion (indel) 
formation
(a,b) TMP- and 4OHT-dose-dependent control of on- and off-target activity of 
DD.SpCas9.DD targeting VEGFA (a) or EMX1 (b). HEK293T cells were transfected with 
SpCas9, DHFR.SpCas9.DHFR, or ER50.SpCas9.ER50 and treated as indicated with 
vehicle, TMP, or 4OHT for 48 h before genomic DNA extraction and analysis of on-target 
and off-target indel frequencies by next-generation sequencing. (c,d) Ratiometric 
representation of on-target:off-target indel frequencies of DD.SpCas9.DD for VEGFA (c) 
and EMX1 (d). (e) Temporal control of DHFR.SpCas9.DHFR-mediated genome editing 
analyzed by an eGFP disruption assay. U2OS.eGFP-PEST cells nucleofected with a plasmid 
expressing DHFR.SpCas9.DHFR and an sgRNA targeting eGFP were incubated with TMP 
for increasing periods of time (6–48 h) before media swap to remove TMP. eGFP+ cells 
were counted using automated, high-content imaging microscopy. Error bars represent 
±s.e.m. from biological replicates (n = 4 (a–d) or 5 (e)).
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